<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000614.v1.p1" parentStudy="phs000614.v1.p1" createDate="2013-04-18" modDate="2013-07-22">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Co-Principal Investigator</td><td>Keith L. Ligon, MD, PhD</td><td>Dana-Farber Cancer Institute, Boston Children&#39;s Hospital, MA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Rameen Beroukhim, MD, PhD</td><td>Dana-Farber Cancer Institute, Brigham and Women&#39;s Hospital, Broad Institute of MIT and Harvard, MA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Peleg Horowitz, MD, PhD</td><td>Brigham and Women&#39;s Hosptial, Dana-Farber Cancer Institute, MA, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Lori Ramkissoon, PhD</td><td>Dana-Farber Cancer Institute, MA, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Azra Ligon, PhD</td><td>Brigham and Women&#39;s Hospital, MA, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Genomic Analysis of Pediatric Low Grade Gliomas</StudyNameEntrez>
	<StudyNameReportPage>Genomic Analysis of Pediatric Low Grade Gliomas</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Case Set</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Pediatric low-grade gliomas (PLGGs) are among the most common solid tumors in children but, apart from mutations or duplications in the BRAF kinase in specific subclasses, few genetic driver events are known. Diffuse PLGGs compose a set of uncommon subtypes that exhibit invasive growth and are therefore especially challenging clinically. These tumors are particularly poorly understood. We performed high-resolution copy-number analysis of 44 diffuse PLGGs to identify recurrent alterations. Diffuse PLGGs exhibited fewer such alterations than adult low-grade gliomas, but we identified several significantly recurrent events. The most significant event, 8q13.1 gains, was observed in 28% of diffuse astrocytoma WHO grade II (DA2) and resulted in partial duplication of the transcription factor MYBL1 with truncation of its C-terminal negative-regulatory domain. A similar recurrent deletion-truncation breakpoint was identified in two angiocentric gliomas in the related gene MYB on 6q23.3. Whole genome sequencing of a MYBL1-rearranged diffuse astrocytoma grade II demonstrated MYBL1 tandem duplication and few other events. Two truncated MYBL1 transcripts identified in this tumor induced anchorage-independent growth when expressed in 3T3 cells and tumor formation in nude mice. Truncated transcripts were also expressed in two additional tumors with MYBL1 partial duplication. Our results define clinically relevant molecular subclasses of diffuse PLGGs and highlight a potential role for the MYB family in the biology of low-grade gliomas. "Reprinted from www.pnas.org/cgi/doi/10.1073/pnas.1300252110 with permission from PNAS." </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Excluded patients &#62; 21 years of age</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23633565"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Astrocytoma"/>
	</Diseases>
	<Attributions>
		<Header title="Co-Principal Investigator">
			<AttName>Keith L. Ligon, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Boston Children&#39;s Hospital, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Rameen Beroukhim, MD, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, Brigham and Women&#39;s Hospital, Broad Institute of MIT and Harvard, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Peleg Horowitz, MD, PhD</AttName>
			<Institution>Brigham and Women&#39;s Hosptial, Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Lori Ramkissoon, PhD</AttName>
			<Institution>Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Azra Ligon, PhD</AttName>
			<Institution>Brigham and Women&#39;s Hospital, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Mark Kieran, MD</AttName>
			<Institution>Boston Children&#39;s Hospital, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Sandro Santagata, MD, PhD</AttName>
			<Institution>Boston Children&#39;s Hospital, Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Charles Stiles</AttName>
			<Institution>Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>William C. Hahn</AttName>
			<Institution>Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Laura E. MacConaill</AttName>
			<Institution>Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Gad Getz</AttName>
			<Institution>Broad Institute of MIT and Harvard, MA, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Matthew D. Ducar</AttName>
			<Institution>Dana-Farber Cancer Institute, MA, USA</Institution>
		</Header>
		<Header title="Other Investigator">
			<AttName>Paul van Hummelen</AttName>
			<Institution>Dana-Farber Cancer Institute. MA, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-PBDPBC-NPU-MDS" longName="Disease-Specific (Pediatric Brain Disorders and Pediatric Brain Cancer, NPU, MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000614.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000614.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000614.v1.p1" FileName="eNCI_0168_DUC_04.15.2013.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Pediatric Brain Disorders and Pediatric Brain Cancer, NPU, MDS)</ConsentName>
        <ConsentAbbrev>DS-PBDPBC-NPU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Pediatric Brain Disorders and Pediatric Brain Cancer.
Use of the data is limited to not-for-profit organizations.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
